Tacrolimus 0.1% vs mometasone furoate ointment
Primary outcome 3: Adverse events · people with moderate to severe chronic relapsing dyshidrotic eczema on hands
1 finding from 1 review
- no estimate extracted1 study · 16 participantsModerate
Findings
What do systematic reviews say?
1,078 questions · 1,098 findings · 33 reviews · Skin
No studies found 396 · 36.1%GRADE not reported 89 · 8.1%Very low 181 · 16.5%Low 183 · 16.7%Moderate 196 · 17.9%High 53 · 4.8%
Tacrolimus 0.1% vs mometasone furoate ointment
Secondary: investigator‐rated reduction in severity ‐ DASIb · people with moderate to severe chronic relapsing dyshidrotic eczema on hands
1 finding from 1 review
- no estimate extracted1 study · 16 participantsModerate
Tacrolimus 0.1% vs vehicle
Primary: investigator‐rated good/excellent control of symptoms · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…
Topical calcineurin inhibitors: tacrolimus 0.1% ointment probably leads to higher primary: investigator‐rated good/excellent control of symptoms compared with vehicle (moderate certainty).
1 finding from 1 review
- RR 29 [1.9, 443.25]1 study · 28 participantsModerate
Corticosteroid creams/ointments: clobetasol propionate foam vs vehicle foam
Primary: participant‐rated good/excellent control of symptoms · participants with moderate to severe hand eczema
Corticosteroid creams/ointments: clobetasol propionate foam probably leads to higher primary: participants with self‐rated good/excellent control of… compared with vehicle foam (moderate certainty).
1 finding from 1 review
- RR 2.32 [1.38, 3.91]1 study · 125 participantsModerate
Tacrolimus 0.1% vs vehicle
Primary: participant‐rated good/excellent control of symptoms Not measured · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Tacrolimus 0.1% vs vehicle
Primary: adverse events ‐ burning/itching at application site · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…
Topical calcineurin inhibitors: tacrolimus 0.1% ointment showed no clear difference in primary: adverse events ‐ burning/itching at application site compared with vehicle (moderate certainty).
1 finding from 1 review
- RR 9 [0.53, 152.93]1 study · 28 participantsModerate
Tacrolimus 0.1% vs vehicle
Secondary: investigator‐rated reduction in severity ‐ Not measured · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Oral immunosuppressants: oral cyclosporin vs topical betamethasone dipropionate
Primary: investigator‐rated good/excellent control of symptoms · people with hand eczema, continuously for 6 months, significant disability, inadequate response to conventional treatment, confirmation by…
Oral immunosuppressants: oral cyclosporin showed no clear difference in primary: investigator‐ rated good/excellent control of symptomsb compared with topical betamethasone dipropionate (moderate certainty).
1 finding from 1 review
- RR 1.88 [0.88, 3.99]1 study · 34 participantsModerate
Oral immunosuppressants: oral cyclosporin vs topical betamethasone dipropionate
Primary: participant‐rated good/excellent control of symptoms · people with hand eczema, continuously for 6 months, significant disability, inadequate response to conventional treatment, confirmation by…
Oral immunosuppressants: oral cyclosporin showed no clear difference in primary: participant‐rated good/excellent control of symptomsb compared with topical betamethasone dipropionate (moderate certainty).
1 finding from 1 review
- RR 1.25 [0.69, 2.27]1 study · 34 participantsModerate
Oral immunosuppressants: oral cyclosporin vs topical betamethasone dipropionate
Number of participants with any adverse event (primary tolerability outcome) · people with hand eczema, continuously for 6 months, significant disability, inadequate response to conventional treatment, confirmation by…
Oral immunosuppressants: oral cyclosporin showed no clear difference in primary: adverse events ‐ at least 1 adverse event compared with topical betamethasone dipropionate (moderate certainty).
1 finding from 1 review
- RR 1.22 [0.8, 1.86]1 study · 55 participantsModerate
Oral immunosuppressants: oral cyclosporin vs topical betamethasone dipropionate
Secondary: investigator‐rated reduction in severity ‐ DASIb · people with hand eczema, continuously for 6 months, significant disability, inadequate response to conventional treatment, confirmation by…
1 finding from 1 review
- no estimate extracted1 study · 34 participantsModerate
Oral retinoids: alitretinoin 30 mg vs placebo
Primary: investigator‐rated good/excellent control of symptoms · people with moderate to severe chronic hand eczema
Oral retinoids: alitretinoin 30 mg leads to higher primary: investigator‐rated good/excellent control of symptoms compared with placebo (high certainty).
1 finding from 1 review
- RR 2.75 [2.2, 3.43]2 studies · 1210 participantsHigh
Oral retinoids: alitretinoin 30 mg vs placebo
Primary: participant‐rated good/excellent control of symptoms · people with moderate to severe chronic hand eczema
Oral retinoids: alitretinoin 30 mg leads to higher primary: participant‐rated good/excellent control of symptoms… compared with placebo (high certainty).
1 finding from 1 review
- RR 2.75 [2.18, 3.48]2 studies · 1210 participantsHigh
Oral retinoids: alitretinoin 30 mg vs placebo
Adverse effects: headache · people with moderate to severe chronic hand eczema
Oral retinoids: alitretinoin 30 mg leads to higher primary: adverse events ‐ headache Folluw‐up: 48 weeks to 72 weeks compared with placebo (high certainty).
1 finding from 1 review
- RR 3.43 [2.45, 4.81]2 studies · 1210 participantsHigh
Corticosteroid creams/ointments: clobetasol propionate foam vs vehicle foam
Number of participants with any adverse event (primary tolerability outcome) · participants with moderate to severe hand eczema
Corticosteroid creams/ointments: clobetasol propionate foam showed no clear difference in primary: adverse events ‐ at least 1 adverse event compared with vehicle foam (moderate certainty).
1 finding from 1 review
- RR 2.24 [0.82, 6.06]1 study · 125 participantsModerate
Oral retinoids: alitretinoin 30 mg vs placebo
Secondary: investigator‐rated reduction in severity in TLSSc and mTLSSd · people with moderate to severe chronic hand eczema
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Oral retinoids: alitretinoin 10 mg vs placebo
Primary: investigator‐rated good/excellent control of symptoms · people with moderate to severe chronic hand eczema
Oral retinoids: alitretinoin 10 mg leads to higher primary: investigator‐rated good/excellent control of symptoms compared with placebo (high certainty).
1 finding from 1 review
- RR 1.58 [1.2, 2.07]2 studies · 781 participantsHigh
Oral retinoids: alitretinoin 10 mg vs placebo
Primary: participant‐rated good/excellent control of symptoms · people with moderate to severe chronic hand eczema
Oral retinoids: alitretinoin 10 mg leads to higher primary: participant‐rated good/excellent control of symptoms compared with placebo (high certainty).
1 finding from 1 review
- RR 1.73 [1.25, 2.4]2 studies · 765 participantsHigh
Oral retinoids: alitretinoin 10 mg vs placebo
Primary outcome 3: Adverse events · people with moderate to severe chronic hand eczema
Oral retinoids: alitretinoin 10 mg showed no clear difference in primary: all adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- RR 1.01 [0.66, 1.55]1 study · 158 participantsModerate
Oral retinoids: alitretinoin 10 mg vs placebo
Secondary: investigator‐rated reduction in severity of TLSSd · people with moderate to severe chronic hand eczema
1 finding from 1 review
- no estimate extracted1 study · 158 participantsModerate